进入重症监护室的COVID-19患者的甲慢性治疗:一项探索性研究
Mohammad Abusamak1,2, Ali Ait Hssain3,4,5, Venkateswara Rao Chinta6
1Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC, Canada.
将德克萨米他 (一种类固醇) 与身体的自然昼夜节律保持一致,特别是在晚上,与COVID-19死亡率的降低有关. 这一发现支持慢性治疗治疗严重疾病.
科学领域:
- 免疫学
- 药理学
- 时间生物学
背景情况:
- 德克萨可以通过控制细胞因子释放风暴 (CRS) 来减轻COVID-19的死亡率.
- 免疫反应和CRS介质表现出昼夜节律,在晚上达到峰值.
- 晚上服用抗炎药物可以加强CRS的治疗.
研究的目的:
- 调查住院COVID-19患者的德克萨梅他松服药时间和死亡率之间的联系.
- 探索昼夜计时德克萨梅他治疗的潜在益处.
主要方法:
- 卡塔尔875名COVID-19患者的回顾性队列研究 (2020年3月至2021年4月).
- 暴露组:德克萨梅他在16:00至04:00之间使用.
- 对照组:德克萨梅他在上午4点至下午4点之间.
主要成果:
- 161名患者晚上接受了德克萨米他; 714名患者白天接受了德克萨米他.
- 在调整了混杂因素后,晚上德克萨梅他 (16: 00- 4: 00) 与COVID-19死亡率显著降低 (OR: 0. 22, 95% CI: 0. 06, 0. 84).
结论:
- 循环定时的德克萨梅他松给药与住院的COVID-19患者的死亡率有显著的相关性.
- 根据身体的内部时钟量身定制德克萨梅他治疗可能会改善严重的COVID-19的临床结果.
更多相关视频
09:36Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
08:25Polar Histogram Visualization of Acute Stress Disorder Scale Scores for Comprehensive Clinical Assessment
Published on: December 6, 2024
相关概念视频
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
